Clinical Trial News Archive - August 2022
August 1, 2022
- Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus
- New Once-Weekly Transdermal Alzheimer's Dementia Therapy Adlarity Provides Drug Delivery Equivalent to Oral Donepezil With Favorable GI Side Effect Profile
August 2, 2022
- Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia
- Positive Results Announced from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq with ENHANZE in Advanced Non-Small Cell Lung Cancer
August 3, 2022
- Pfizer to Discontinue Development Program for PF-07265803 for LMNA-Related Dilated Cardiomyopathy
- Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo in Advanced Metastatic Castration-resistant Prostate Cancer
August 4, 2022
- Novavax Announces Initiation of Phase 2b/3 Hummingbird Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years
- Monoclonal Antibody Prevents Malaria in U.S. Adults, NIH Trial Shows
August 5, 2022
August 8, 2022
- Cocrystal Pharma to Conduct Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344
- Tagrisso Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial
- Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
- Lilly's Taltz (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience
- HERTHENA-Lung02 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
August 9, 2022
- Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder
- Monkeypox Update: FDA Authorizes Emergency Use of Jynneos Vaccine to Increase Vaccine Supply
- Datopotamab Deruxtecan-Based Combinations Show Promising Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer
August 10, 2022
August 11, 2022
- Monoclonal Antibody Reduces Asthma Attacks in Urban Youth
- Todos Medical Completes Trial Design for Tollovid Long COVID Clinical Study in Adults
August 12, 2022
- Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants
- Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older
August 15, 2022
- Anixa Biosciences Announces Treatment of First Patient in its Ovarian Cancer CAR-T Clinical Trial
- Novavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older
August 16, 2022
August 17, 2022
- FDA Accepts for Review Pfizer’s Supplemental Application for Abrilada™ (adalimumab-afzb) Interchangeability
- PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
- CSL Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema
August 18, 2022
- GenFleet Receives FDA Approval for Phase II Study of RIPK1 Inhibitor GFH312
- FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib
August 19, 2022
- U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Adolescents Aged 12 Through 17
- Lundbeck's Migraine Drug Hits Roadblock in Phase III
August 22, 2022
- Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S.
- Novo Nordisk Successfully Completes Phase 2 Trial with CagriSema in People with Type 2 Diabetes
- Vaderis Therapeutics AG Emerges from Stealth and Announces Initiation of Clinical Proof-of-Concept Trial in HHT
- Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
- Marijuana and Hallucinogen Use Among Young Adults Reached All-Time High in 2021
- U.S. Centers for Disease Control and Prevention Expands Recommendation for Novavax COVID-19 Vaccine, Adjuvanted to Adolescents Aged 12 Through 17
August 23, 2022
- Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
- Moderna Completes Application To U.S. Food And Drug Administration For Emergency Use Authorization Of Omicron-Targeting Bivalent Covid-19 Booster Vaccine, mRNA-1273.222
- Amgen Announces Positive Top-Line Results From Phase 3 Study of ABP 959, Biosimilar Candidate to Soliris® (eculizumab)
- Merck Receives Fast Track Designation from the U.S. FDA for MK-2060, an Investigational Anticoagulant Therapy
- Modified bladder cancer treatment shows promise
August 24, 2022
August 25, 2022
- Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
- Anthos Therapeutics Launches Second Phase 3 Clinical Trial of Its Dual-acting Factor XI Inhibitor, Abelacimab
- Alvotech Initiates Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva
- TG Therapeutics Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS Published in The New England Journal of Medicine
August 27, 2022
August 28, 2022
August 29, 2022
- Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
- SARS-CoV-2 Antigen Levels Linked to Patient Outcomes
- NIH Study of Tea Drinkers in the UK Suggests Health Benefits for Black Tea
August 30, 2022
- Aristea Therapeutics Announces Dosing of First Patient in Phase 2a Trial of RIST4721 in Hidradenitis Suppurativa
- Researchers Identify Possible Target for a Type of Sporadic ALS
- FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study
- FDA Grants Priority Review to Efanesoctocog Alfa for People with Hemophilia A
August 31, 2022
- First U.S. Patient Receives Autologous Stem Cell Therapy to Treat Dry AMD
- Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Adults 18 Years and Older
- Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster
Clinical trial results archive
- 2024
- January, February, March, April, May
- 2023
- January, February, March, April, May, June, July, August, September, October, November, December
- 2022
- January, February, March, April, May, June, July, August, September, October, November, December
- 2021
- January, February, March, April, May, June, July, August, September, October, November, December
- 2020
- January, February, March, April, May, June, July, August, September, October, November, December
- 2019
- January, February, March, April, May, June, July, August, September, October, November, December
- 2018
- January, February, March, April, May, June, July, August, September, October, November, December
- 2017
- May, June, July, August, September, October, November, December
- 2016
- October
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.